2025 Q2 -tulosraportti
126 päivää sitten37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
3 481
Myynti
Määrä
22 332
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
1,198VWAP
Alin
1,16VaihtoMäärä
0,7 572 965
VWAP
Ylin
1,198Alin
1,16VaihtoMäärä
0,7 572 965
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·31.12.2025 · MuokattuA small New Year's greeting from me.. Haven't checked if my informal prediction earlier this year that Circio would be this year's bio winner stock has come true. Nordnet reports approx 64% increase last year, 86% last 6 months and 90 last 3 months. That's pretty good. 2025 has been the year where the turnaround with the development of new technology was completed. Atlas financed the company for 2 1/2 years with the help of the shareholders who bought converted shares at par value, a period when "everyone" talked the stock down. That time is over now and Atlas is concluded and out. Now in January, the shareholders will undertake a new "collective effort" and I believe the share issue will be the last opportunity for entry at a very low mcap. The reason I believe this is that news and results are queuing up in the coming months. Results from own projects and collaborations with partners are coming and the first ones are probably not far off. New eye and CNS results with version 3.2 and 4.0 are ongoing. NeoRegen entered in vivo testing 30 June after POC was established between circVec and Nicht teknologien. Celle prenetssjonsteknologi. In August it was announced that Entos had proceeded with its PLV Fusogenic reknologi. Now in November, info came that there was at least 6 months effect, probably longer with LNP so that probably means that Certest is continuing and that the virnkngen in spleen is probably longer. Danon and AMW have been initiated and several other projects and partner testing are ongoing. There's a lot going on. Probably the first news will komer now in January. There is a long subscription period from 14 Jan to the beginning of February. The company has thus given itself ample time to complete projects and serve up goodies during this period. It is a preferential share issue for those shareholders who have contributed to the turnaround and who own shares as of 12. Januar. If news comes, the reward is being able to subscribe for shares for 1 kr for the loyal ones. I believe this share issue, which is set up completely by the book and very shareholder-friendly, is "pay back" to all of us who enter the new year as shareholders. Happy New Circio Year to all.
·30.12.2025Quiet here
·30.12.2025Well, there's not much to say, one really has to be comfortable with red numbers to keep up here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
126 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31.12.2025 · MuokattuA small New Year's greeting from me.. Haven't checked if my informal prediction earlier this year that Circio would be this year's bio winner stock has come true. Nordnet reports approx 64% increase last year, 86% last 6 months and 90 last 3 months. That's pretty good. 2025 has been the year where the turnaround with the development of new technology was completed. Atlas financed the company for 2 1/2 years with the help of the shareholders who bought converted shares at par value, a period when "everyone" talked the stock down. That time is over now and Atlas is concluded and out. Now in January, the shareholders will undertake a new "collective effort" and I believe the share issue will be the last opportunity for entry at a very low mcap. The reason I believe this is that news and results are queuing up in the coming months. Results from own projects and collaborations with partners are coming and the first ones are probably not far off. New eye and CNS results with version 3.2 and 4.0 are ongoing. NeoRegen entered in vivo testing 30 June after POC was established between circVec and Nicht teknologien. Celle prenetssjonsteknologi. In August it was announced that Entos had proceeded with its PLV Fusogenic reknologi. Now in November, info came that there was at least 6 months effect, probably longer with LNP so that probably means that Certest is continuing and that the virnkngen in spleen is probably longer. Danon and AMW have been initiated and several other projects and partner testing are ongoing. There's a lot going on. Probably the first news will komer now in January. There is a long subscription period from 14 Jan to the beginning of February. The company has thus given itself ample time to complete projects and serve up goodies during this period. It is a preferential share issue for those shareholders who have contributed to the turnaround and who own shares as of 12. Januar. If news comes, the reward is being able to subscribe for shares for 1 kr for the loyal ones. I believe this share issue, which is set up completely by the book and very shareholder-friendly, is "pay back" to all of us who enter the new year as shareholders. Happy New Circio Year to all.
- ·30.12.2025Quiet here·30.12.2025Well, there's not much to say, one really has to be comfortable with red numbers to keep up here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
3 481
Myynti
Määrä
22 332
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
1,198VWAP
Alin
1,16VaihtoMäärä
0,7 572 965
VWAP
Ylin
1,198Alin
1,16VaihtoMäärä
0,7 572 965
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Datan lähde: FactSet, Quartr
2025 Q2 -tulosraportti
126 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31.12.2025 · MuokattuA small New Year's greeting from me.. Haven't checked if my informal prediction earlier this year that Circio would be this year's bio winner stock has come true. Nordnet reports approx 64% increase last year, 86% last 6 months and 90 last 3 months. That's pretty good. 2025 has been the year where the turnaround with the development of new technology was completed. Atlas financed the company for 2 1/2 years with the help of the shareholders who bought converted shares at par value, a period when "everyone" talked the stock down. That time is over now and Atlas is concluded and out. Now in January, the shareholders will undertake a new "collective effort" and I believe the share issue will be the last opportunity for entry at a very low mcap. The reason I believe this is that news and results are queuing up in the coming months. Results from own projects and collaborations with partners are coming and the first ones are probably not far off. New eye and CNS results with version 3.2 and 4.0 are ongoing. NeoRegen entered in vivo testing 30 June after POC was established between circVec and Nicht teknologien. Celle prenetssjonsteknologi. In August it was announced that Entos had proceeded with its PLV Fusogenic reknologi. Now in November, info came that there was at least 6 months effect, probably longer with LNP so that probably means that Certest is continuing and that the virnkngen in spleen is probably longer. Danon and AMW have been initiated and several other projects and partner testing are ongoing. There's a lot going on. Probably the first news will komer now in January. There is a long subscription period from 14 Jan to the beginning of February. The company has thus given itself ample time to complete projects and serve up goodies during this period. It is a preferential share issue for those shareholders who have contributed to the turnaround and who own shares as of 12. Januar. If news comes, the reward is being able to subscribe for shares for 1 kr for the loyal ones. I believe this share issue, which is set up completely by the book and very shareholder-friendly, is "pay back" to all of us who enter the new year as shareholders. Happy New Circio Year to all.
- ·30.12.2025Quiet here·30.12.2025Well, there's not much to say, one really has to be comfortable with red numbers to keep up here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
3 481
Myynti
Määrä
22 332
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
1,198VWAP
Alin
1,16VaihtoMäärä
0,7 572 965
VWAP
Ylin
1,198Alin
1,16VaihtoMäärä
0,7 572 965
Välittäjätilasto
Dataa ei löytynyt